CEO of World's Leading Regenerative Medicine Company, Organogenesis, Gives Keynote Address at World Congress of Regenerative Medicine in Germany

Outlines Pathways to Profitability for Emerging Industry; Hundreds of Thousands of Patients Already Treated Worldwide

Leipzig, Germany / Canton, Massachusetts—October 18, 2007—The prestigious 3rd Annual World Congress of Regenerative Medicine is kicking off today in Leipzig, Germany with an opening keynote address from Geoff MacKay, CEO of Organogenesis, Inc.

The Congress invited MacKay to speak to the world's top scientific and business leaders in cell biology and bio-engineering, to discuss Organogenesis' role as the first company to have translated the exciting science of regenerative medicine into a profitable, and scalable, business model.

MacKay's speech, which outlines pathways to profitability for the emerging field of regenerative medicine, will also discuss "RegenMed 1.0" and "RegenMed 2.0," terms coined by Chris Mason in a recent publication of the journal Regenerative Medicine. RegenMed 2.0 is the more pragmatic second phase within the development of this new field of medicine, moving beyond a purely research-driven focus into full commercialization of new cell-based therapies. With scientific hurdles overcome and potential therapies discovered, oftentimes companies face larger hurdles when transitioning from research entities into full-fledged commercial organizations.

"RegenMed 2.0 is already here," says MacKay. "Patients' lives are being transformed around the world, due to the work of many people attending the World Congress. Regenerative medicine companies can, and need to, evolve into successful entities, focused on business fundamentals in order to continue the work that has been started."

As encouragement to the industry, MacKay will also outline the successful business strategies that Organogenesis has pursued to become the first profitable regenerative medicine company. He will discuss a model for companies exploring commercialization in regenerative medicine, and detail how Organogenesis has successfully translated science from this field into commercial therapies benefiting patients today.

The field of regenerative medicine has now reached the stage of translating groundbreaking science into viable product offerings. Challenges in the field of "living technology" include product design, clinical development, mass production, and distribution of a living product safely, reliably, and economically. Unlike traditional medicines, living cells are delicate, have a short lifespan, and thus pose tremendous challenges to deliver in the form of therapies.

Organogenesis is the first company to successfully mass produce living regenerative medicine products—reaching hundreds of thousands of patients—and to have reached sustained profitability. Its signature product, Apligraf^®, is the first bio-engineered cell therapy to have received FDA approval, and is used by doctors successfully in treating patients with diabetic foot ulcers and venous leg ulcers in the U.S. and other markets across the world.

Organized by the Fraunhofer Institute for Cell Therapy and Immunology (IZI), the 3rd World Congress of Regenerative Medicine is being held in Leipzig, Germany from October 18–20, 2007 at the Congress Center Leipzig.

The World Congress represents an international cohort of scientists, business leaders and regulatory experts. During the Congress, internationally renowned scientists from many different countries will be presenting their latest findings on stem cell technology. The papers will concentrate on bone tissue, cartilage, immunology, skin and nerves, as well as new types of imaging techniques in connection with regeneration. Discussion and exchange of information on these topics will extend from academia to industry.

Also an invited speaker is Dr. Vincent Ronfard, Chief Science Officer of Organogenesis, who will chair a session of scientists focusing on the utilization of natural biomaterials as a source material for regenerative medicine products.

MacKay will also speak next month regarding commercializing regenerative medicine at the 5th Annual Commercial Translation for Regenerative Medicine conference in London on November 14-15.

About Regenerative Medicine

A new frontier in healthcare, regenerative medicine is an evolving therapeutic approach that utilizes living cells to repair or replace body tissue damaged by injury, disease or the aging process . It is a multidisciplinary field involving biology, medicine and engineering.

Regenerative therapies rely on the body's own natural ability to repair and regenerate, and enable the body to heal itself Regenerative medicine also empowers scientists to grow living cells, tissues and organs in the laboratory, and to safely implant them into the human body for the purposes of healing.

The related terms "Tissue Regeneration," "Tissue Engineering" and "Stem Cell Therapies" are often used to refer to some of the activities under the umbrella of regenerative medicine.

About Organogenesis, Inc.